Persistent Transmission of HCV among Men Who Have Sex with Men despite Widespread Screening and Treatment with Direct-Acting Antivirals

Stephanie Popping 1,2,* Lize Cuypers 3,4, Mark A. A. Claassen 5, Guido E. van den Berk 6, Anja De Weggheleire 7, Joop E. Arends 8, Anne Boerekamps 2, Richard Molenkamp 1, Marion P. G. Koopmans 1, Annelies Verbon 2,8, Charles A. B. Boucher 1,4, Bart Rijnders 2,4 and David A. M. C. van de Vijver 1,4

1 Department of Viroscience, Erasmus Medical Center, 3015 CA Rotterdam, The Netherlands
2 Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, 3015 CA Rotterdam, The Netherlands
3 Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium
4 Department of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, Belgium
5 Department of Internal Medicine and Infectious Diseases, Rijnstate Ziekenhuis, 6815 AD Arnhem, The Netherlands
6 Department of Internal Medicine and Infectious Diseases, OLVG, 1091 AC Amsterdam, The Netherlands
7 Department of Clinical Science, Institute of Tropical Medicine Antwerp, 2000 Antwerp, Belgium
8 Department of Internal Medicine and Infectious Diseases, Universitair Medisch Centrum Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands

* Correspondence: s.popping@erasmusmc.nl; Tel.: +31-10-17-03-87-56
† This author has passed away.
‡ These authors contributed equally to this work.

Abstract: Background: In the Netherlands, unrestricted access to direct-acting antivirals (DAAs) halved the incidence of acute hepatitis C virus (HCV) infections among HIV-infected men who have sex with men (MSM). To develop strategies that can further reduce the spread of HCV, it is important to understand the transmission dynamics of HCV. We used phylogenetic analysis of a dense sample of MSM to provide insight into the impact of unrestricted access to DAAs on HCV transmission in the Netherlands and in Belgium. Methods: We included 89 MSM that were recently infected with HCV genotype 1a in ten Dutch and one Belgian HIV treatment centers. Sequences were generated using next gene sequencing and Sanger sequencing. Maximum likelihood phylogenetic analysis (general time reversible model) was performed on concatenated NS5A and NS5B sequences and a reference set of 389 highly similar control sequences selected from GenBank. A cluster was based on a minimum bootstrap support of 90% and a 3% genetic distance threshold. Results: We found that 78 (88%) of individuals were part of seven major clusters. All clusters included individuals from across the study region, however, different cities were part of different clusters. In three clusters, HIV-negative MSM clustered with sequences from HIV-positive MSM. All clusters that were observed before the introduction of DAAs persisted after unrestricted access to DAAs became available. Conclusion: Recently acquired HCV infections among MSM in the Netherlands and Belgium are strongly clustered and therefore highly suitable for targeted prevention strategies, such as contact tracing and partner notification. Importantly, despite an HCV incidence reduction after high DAA uptake and continuously monitoring, HCV transmission persisted in the same clusters.

Keywords: hepatitis c; transmission dynamics; phylogenetic analysis; HIV-infected Men-who-have-sex-with-men; hepatitis C elimination

1. Introduction

The World Health Organization (WHO) set the goal to eliminate hepatitis C virus (HCV) as a global health threat by 2030. The WHO wants to achieve this ambitious goal by
reducing the number of new HCV infections by 90% and by reducing HCV-related mortality by 65% in 2030 [1]. A key element of the WHO’s strategy of elimination is the expansion of HCV treatment with highly curative direct-acting antivirals (DAA) and thereby preventing onward transmission to others.

A recommended strategy to reach the goals set by the WHO is by a micro-elimination approach: the local scale-up of identifying new infections and DAA treatment in well-defined populations that actively contribute to the HCV epidemic. An effort to achieve micro-elimination was made in the Netherlands among HIV-infected men who have sex with men (MSM), which is the predominant Dutch population in whom HCV is actively transmitted. The micro-elimination approach included HCV testing every six months followed by immediate DAA treatment in HCV-infected people [2,3]. Although this effort of testing and expanded treatment access strongly reduced the number of acute infections by 50%, micro-elimination was not reached, as HCV continues to be transmitted [4].

Several Western European countries report high numbers of new HCV infections and re-infections among HIV co-infected MSM, which are mainly driven by ongoing engagement in high-risk behaviour [4–6]. Moreover, more reports mentioned the presence of HCV among HIV-negative MSM [7–9]. In addition to local transmission, HCV infections can be imported or acquired elsewhere and continue to seed the local epidemic, since viruses do not respect national borders [10]. Therefore, a better understanding of the effect of unrestricted DAA therapy on the transmission of recently acquired HCV among MSM is needed to select appropriate future interventions and to improve micro-elimination strategies.

In this study we use phylogenetic analysis to provide further insight into HCV transmission among mostly HIV-infected MSM with a HCV infection acquired before and after DAAs became unrestrictedly available: in the Netherlands and Belgium since 2015 and 2017, respectively. Similar as to the Netherlands the HCV epidemic in Belgium is mainly concentrated among MSM.

2. Methods
2.1. Study Population of Acutely Infected HCV Genotype 1a Individuals

Plasma samples from MSM with recently acquired HCV genotype 1a infections who participated in two Dutch Acute HCV in HIV studies (DAHHS) were collected between 2013–2014 and 2016–2018. Both DAHHS studies were single-arm, open-label, multicenter studies, investigating the efficacy of DAA therapies in mostly HIV-positive MSM with a recently acquired HCV infection [11,12]. A detailed description of the studies and patient inclusion criteria can be found elsewhere [11,12]. In summary, both DAHHS studies enrolled participants identified with an acute HCV infection during routine clinical care in ten different Dutch HIV treatment centers. Additionally, during the DAHHS 2 study, one Belgian HIV treatment center (Antwerp) participated, and patients from all over Belgium were referred to this center for participation to the study. In both studies, patients were included if HCV was diagnosed within six months after HCV infection, as described elsewhere [11,12]. All patients gave written informed consent for the use of their blood samples for research purposes [11,12].

The first DAHHS study started inclusions in September 2013 and lasted until December 2014. HCV genotype 1a acutely infected HIV-positive MSM (n = 57) were treated with boceprevir, pegylated interferon, and ribavirin for 12 weeks at a time when interferon-free treatment was yet unavailable [11].

The DAHHS 2 study started inclusion in February 2016 and ended in March 2018, where the impact of grazoprevir and elbasvir was studied for 8 weeks among 86 MSM acutely infected with HCV. Among those, 51 had a genotype 1a infection. Most of the patients were HIV-positive MSM, however, the study also included a small number (n = 4) of HIV-negative MSM [12].
2.2. Viral Sequencing of the Non-Structural Proteins 5A and 5B

Two methods for sequencing were used in the two DAHHS studies, respectively: next-generation sequencing (NGS) in DAHHS 1 and Sanger population sequencing in DAHHS 2 [11,12]. In short, DAHHS 1 samples were sequenced by NGS on the Illumina MiSeq platform, as previously published [13]. The CLC Genomics Workbench (version 7.5/7.5.1) including the CLC Microbial Genome Finishing Module (version 1.4, Qiagen, Hilden, Germany), was used to process the raw reads into full genome consensus sequences. Trimmed reads were pre-filtered against a GenBank reference list containing 953 partial and complete HCV genomes, followed by the sampling of a subset of 50,000 to 100,000 HCV-specific sequence reads for the de novo assembly of whole genomes [13]. For subsequent phylogenetic and resistance analysis, only the nucleotide sequences of the NS5A and NS5B region were used. For the DAHHS 2 samples, solely the NS5A and NS5B genes were amplified by PCR and subsequently sequenced by Sanger sequencing as described before [12].

2.3. Phylogenetic Analysis to Evaluate Transmission Clustering Patterns

A concatenated alignment of NS5A and NS5B sequences was assembled for 89 samples; in two samples, sequencing was unsuccessful for the NS5A gene [14]. For each of these 89 included sequences, the 80 most highly similar HCV sequences were selected as control sequences from GenBank using the basic local alignment search tool (BLAST) [15]. After removal of duplicate sequences, phylogenetic analysis was reconstructed for 389 sequences, including, 87 study samples and 302 public sequences. We included a genotype 1b sequence (EU482849) to root the phylogenetic tree within the maximum likelihood (ML) framework. The ML tree was reconstructed using a generalized time-reversible nucleotide substitution model (GTR) with 4 discrete gamma rate categories, while accounting for invariable sites, as implemented within the IQTree software [16,17]. Tree robustness was evaluated using 1000 ultra-fast bootstrap replicates and a Shimodaira–Hasegawa-like (SH-like) approximate likelihood ratio test (aLRT) [18]. A cluster was defined based on a minimum ultra-fast bootstrap support of 90%, an aLRT of at least 80%, and a genetic distance threshold of 3% [19]. A transmission pair was defined as two sequences clustering together. The genetic distance was calculated using a Tamura and Nei model using the software MicrobeTrace [20]. Visualization of the clusters was also performed with the software MicrobeTrace. The robustness of our results was evaluated using an alignment of whole genome sequences (n = 44), and subsequently compared to an alignment of concatenated NS5A and NS5B sequences (n = 44) (Supplemental Information).

3. Results

3.1. Study Population

From the 108 males with a genotype 1a HCV infection, 89 samples were available for sequencing. Sequences were generated, of which 44 with NGS (DAHHS 1 study) and 45 with Sanger (DAHHS 2 study). All males had MSM as the transmission route for their HCV infection and all had a recently acquired infection. Almost one fifth of patients (18%) originated from Belgium and others from several Dutch cities, with the majority from Amsterdam (33%) or Rotterdam (22%). Patients were all successfully treated with DAAAs as part of the DAHHS 1 and 2 studies [11].

3.2. Recently Acquired HCV Infections in The Netherlands and Belgium Are Highly Clustered

Phylogenetic analysis of sequences from recently acquired HCV infections showed that 78 of the 89 (88%) individuals included in the study cohort were embedded in one out of the seven identified clusters, and 4 of the 89 (4.5%) formed pairs (Figure 1 and Table 1). We identified four large clusters containing ≥10 individuals (depicted with the numbers II, III, V, and VI in Table 1) (Figure 1).
3.2. Recently Acquired HCV Infections in The Netherlands and Belgium Are Highly Clustered

Phylogenetic analysis of sequences from recently acquired HCV infections showed that 78 of the 89 (88%) individuals included in the study cohort were embedded in one out of the seven identified clusters, and 4 of the 89 (4.5%) formed pairs (Figure 1 and Table 1). We identified four large clusters containing \( \geq 10 \) individuals (depicted with the numbers II, III, V, and VI in Table 1) (Figure 1).

Figure 1. An overview of the clusters and transmission pairs (I–VIII) with a genetic distance threshold <3%. The circles represent HCV infections included prior to the widespread use of DAA therapy (all in HIV-positive MSM). The triangles represent HCV infections among HIV-positive and star among HIV-negative MSM after DAA introduction. The size of the nodes represents the number of sequences to which that particular node was phylogenetically linked. The colours represent the centres where patients were diagnosed with HCV (dark blue = Haarlem, dark green = The Hague, grey = Arnhem, light blue = Amsterdam, light green = Antwerp (Belgium), pink = Maastricht, orange = Utrecht, and red = Rotterdam) The clusters consisted only of study samples and did not include any of the control samples, which mostly originated from other European countries and the United States. The figure is established using Microbe Trace [20].

Table 1. An overview of the clusters and transmission pairs obtained with maximum likelihood phylogenetic reconstruction \( N = 82 \) sequences clustered in a cluster or pair. The other seven were not linked to any of the sequences in our set or reference set. The samples are divided in the ones included between 2013 and 2014 prior to the widespread use of the direct-acting antivirals in 2015 and 2016–2018.

| Phylogenetic Cluster/Pair | I | II | III | IV | V | VI | VII | VIII | IX |
|--------------------------|---|----|-----|----|---|----|-----|------|----|
| Included 2013–2014       | 2 | 7  | 13  | 1  | 7 | 5  | 1   | 1    | 1  |
| Included 2016–2018       | 0 | 3  | 15  | 2  | 11| 5  | 4   | 2    | 1  |
| Total number of MSM      | 2 | 10 | 28  | 3  | 18| 10 | 5   | 3    | 2  |
| Mean genetic distance    | 0.7| 1.9| 1.9 | 1.4| 2.1| 2.1| 1.6 | 0.4  | 1.5|

All clusters showed a very strong geographical variation with mostly three different locations. Interestingly, all clusters, apart from one single cluster (number II in Figure 1), included samples from one of the two major Dutch cities (Amsterdam or Rotterdam) (Figure 1).

Our study was not designed to study the HCV transmission dynamics between HIV-infected and HIV-uninfected MSM. Nevertheless, we found that the acute HCV samples of
four HIV-negative MSM were embedded in clusters, which also consisted of acute HCV samples from HIV-positive MSM (Figure 1). Three clusters included HIV-negative MSM (depicted with number III, IV, and V in Table 1 and Figure 1) and all these individuals were sampled around the end of 2017 and originated from several different geographical locations. Interestingly, cluster IV included only three individuals, of which two were HIV-negative.

3.3. Clusters Persist after Continuously Monitoring and Broadened Access of DAA Therapy in The Netherlands

Although the widespread use of DAAs since 1st of November 2015 resulted in a profound reduction in the number of new HCV infections, little impact was found on the size of the phylogenetic clusters. We identified four clusters of phylogenetically linked HCV infections before the widespread introduction of DAAs in 2015 (number II, III, V, and VI in Table 1 and Figure 1), which were persistent after 2015. Moreover, a new cluster emerged after 2015 (number IV, VII, and VIII).

4. Discussion

This study describes substantial clustering of acute HCV infections in the Netherlands and Belgium. Over 90% of the recently acquired HCV infections were embedded in one of the detected clusters. HCV infections were detected in the years preceding, as well as after DAA therapy introduction, suggesting active transmission of HCV among HIV co-infected MSM. Importantly, this study showed that clusters present prior to the universal access of DAA therapy remained present, despite several elimination strategies, including compulsory notification of public health services of newly diagnosed HCV infections, partner notification and testing, annual HCV testing among HIV-positive MSM, and increased awareness amongst clinicians. Indeed, several Dutch studies show a stabilizing HCV incidence among HIV-infected MSM [21,22]. Our results confirm that unrestricted DAA therapy without other prevention methods led to a reduction in infections, however, will not suffice to micro-eliminate HCV among HIV-infected MSM [23,24].

Apart from persistent clustering, our study provided further insight into the transmission of recently acquired HCV infections, as we identified several clusters, of which four were major clusters with ten or more infections. As most of the recently acquired HCV infections were embedded in large clusters, the Dutch and Belgium HCV epidemics seem highly suitable for targeted prevention strategies. Targeted prevention strategies, such as behavioral interventions and intensified HCV testing in specific risk groups followed by immediate DAA treatment, could therefore be combined to stop HCV transmission in MSM [25,26].

Our data show geographical mixing not only between both neighboring countries, but also between the different Dutch centers. We identified that clusters are large with small genetic distances, and contain several Dutch cities, suggesting local transmission. In agreement with our finding, the Swiss HIV cohort showed an increase in domestic transmission during the period of 2008 and 2016 [27]. Nevertheless, we have indications that clusters could be part of European HCV networks for several reasons [10]. Firstly, we found clusters that embedded infections from Belgium and The Netherlands. Secondly, the largest cluster contained an M28V mutation in 96% of the cluster (described in S.Popping et al. Clin. Infect Diseases 2020) which is also found among HIV-positive MSM in Paris [14,28]. Lastly, data from van de Laar et al. show that samples from Dutch HIV-positive MSM are embedded in large European clusters [10]. Koopsen et al. describe a rise in the proportion of external introductions of new HCV infections in Amsterdam [29]. These findings, combined with our data, can suggest that Amsterdam is one of the entry points of HCV in the Netherlands. This is important information for trying to achieve HCV elimination, as this can guide testing programs and provide a more intensive approach in cities that are entry points. The use of real-time phylogenetic analysis combined with clinical and demographical information could help in identifying active transmission networks that
should get appropriate attention from public health interventions. Moreover, further insights into the local and international transmission nature of new HCV infections are needed to further target elimination strategies. A collaboration with several large cities in Europe was initiated for further exploration.

In agreement with other findings, HIV-uninfected MSM diagnosed with a recently acquired HCV infection belonged to similar clusters also containing HIV-positive MSM [9,30,31]. This supports a model of an HCV spillover among high-risk MSM, regardless of their HIV-status. Importantly, among HIV-negative MSM, viral hepatitis screening is not standardized or regularly performed at sexual transmitted disease (STD) clinics. The actual HCV prevalence and incidence in this population is, therefore, unknown. Among HIV pre-exposure prophylaxis (PrEP) users in Amsterdam, a high baseline HCV prevalence of 4.8% was found, which was 2.9% in a similar cohort in Antwerp [7,8]. Although it is unclear whether these percentages can be extrapolated towards the HIV-negative MSM population with high-risk behavior not engaging in PrEP services. MSM PrEP users are currently monitored for HCV on a regular basis [32]. Moreover, prevention efforts should not be restricted to HIV status but towards risk behavior and thus be expanded towards the high-risk HIV-negative MSM population.

This study has several limitations. Firstly, our controls were sequences submitted to GenBank, of which we know that the majority originated from samples of chronic HCV-infected patients rather than of acutely HCV-infected patients. Moreover, sequences included in GenBank are biased towards studies from countries with resources to perform genetic sequencing. Moreover, most available samples consist only of an NS5B fragment, as it is typically used for genotyping purposes. However, this is a very short stretch with a much lower phylogenetic signal as our concatenated alignment of the NS5A and NS5B genes.

Secondly, the HCV epidemic in the Netherlands is predominantly driven by MSM. New infections due to injection drug use became exceptional [33,34]. We do realize that, in several other countries, injection drug use remains the major driver of the HCV epidemic. However, interaction between MSM and injection drug users is highly unlikely. Additionally, needle sharing among MSM in the context of chemsex only rarely occurs [10,35].

In conclusion, we used well-defined data from the Netherlands and Belgium to unravel the transmission of recently acquired HCV infections among HIV-positive MSM. Our results indicate that recently acquired HCV infections among MSM in the Netherlands and Belgium are strongly clustered. Despite an HCV incidence reduction after high DAA uptake and continuous monitoring, HCV transmission continued to be present in the same clusters as beforehand. This shows that DAA therapy as a standalone intervention proved to be insufficient in obtaining micro-elimination, therefore, we advise to install additional prevention measurements.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/v14091953/s1, Figure S1: Phylogenetic comparison of whole genome sequences versus concatenated NS5A+NS5B sequences of the DAHHS 1 samples. Table S1: Baseline characteristics. Table S2: Phylogenetic comparison of whole genome sequences versus concatenated NS5A+NS5B sequences of the DAHHS 1.

Author Contributions: Designed the study: S.P., B.R. and D.A.M.C.v.d.V.; Analysed the data: S.P., L.C., R.M., B.R. and D.A.M.C.v.d.V.; Data collection: M.A.A.C., G.E.v.d.B., A.D.W., J.E.A., A.B. Interpretation of the results: S.P., L.C., C.A.B.B., A.V., M.P.G.K., R.M., B.R. and D.A.M.C.v.d.V.; Wrote the first draft of the paper: S.P. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a research grant from Health Holland (LSHM15024), an educational grant from Gilead Sciences [NL-2018-000171], a grant from the Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO—project G0B2317N) a research grant from Merck Sharp and Dohme to support the DAHHS1 and 2 studies.
Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki. The institutional review board of all participating centers and the competent authorities of Belgium (DAHHS 2) and the Netherlands approved the study. ClinicalTrials.gov, number NCT01912495 for the DAHHS 1 study and NCT02600325 for the DAHHS 2 study.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the DAHHS 1 and DAHHS 2 studies.

Data Availability Statement: Data is available upon request.

Conflicts of Interest: S.P.: nothing to disclose; L.C.: has nothing to disclose; M.A.A.C.: Dr. Claassen has nothing to disclose; G.E.v.d.B.: no disclosures; A.d.W.: Dr. De Wegheleire has nothing to disclose; J.E.A.: Dr. Arends reports other from Gilead, other from Janssen, other from ViiV, other from MSD, outside the submitted work; A.B.: has no conflict of interest; R.M.: Dr. Molenkamp has nothing to disclose; M.P.G.K.: Dr. Koopmans has nothing to disclose; A.V.: has nothing to disclose; C.B.: received honoraria from ViiV outside of the submitted work; B.R.: reports research grants from Gilead, research grants from Merck Sharp and Dohme and honoraria from Jansen-Cilag, BMS, Pfizer and Viiv; D.v.d.V.: Gilead Sciences, MSD, ViiV, and Jansen & Jansen.

References
1. WHO. Global Hepatitis Report 2017; Geneva: 2017 CC BY-NC-SA 3.0 IGO; World Health Organization: Geneva, Switzerland, 2017.
2. The Lancet HIV. Microelimination could be a big deal for HCV and HIV services. Lancet HIV 2018, 5, e605. [CrossRef]
3. Lazarus, J.V.; Martin, T.C.; Rodger, A.; Stellbrink, H.J.; Mauss, S.; Boesecke, C.; Mandorfer, M.; Bottero, J.; Baumgarten, A.; Ingiliz, P.; Martin, T.C.; Rodger, A.; Stellbrink, H.J.; Mauss, S.; Boesecke, C.; Mandorfer, M.; Bottero, J.; Baumgarten, A.; Siemeling, M.J.; Santos, I.; Troya, J.; Lose, J.E.; et al. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals. AIDS 2019, 33, 685–689. [CrossRef]
4. Boerekamps, A.; van den Berk, G.E.; Lauw, F.N.; Leyten, E.M.; van Kasteren, M.E.; van Eeden, A.; Posthouwer, D.; Claassen, M.A.; Dofferhoff, A.S.; Verhagen, D.W.M.; et al. Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy. Clin. Infect. Dis. 2018, 66, 1360–1365. [CrossRef] [PubMed]
5. Ingiliz, P.; Martin, T.C.; Rodger, A.; Stellbrink, H.J.; Mauss, S.; Boesecke, C.; Mandorfer, M.; Bottero, J.; Baumgarten, A.; Bhagani, S.; et al. HCV re-infection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J. Hepatol. 2017, 66, 282–287. [CrossRef] [PubMed]
6. Berenguer, J.; Gil-Martin, A.; Jarrin, I.; Montes, M.L.; Dominguez, L.; Aldamiz-Echevarria, T.; Tellez, M.J.; Santos, I.; Troya, J.; Losa, J.E.; et al. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals. AIDS 2019, 33, 685–689. [CrossRef]
7. Hoornenborg, E.; Achterberg, R.C.A.; Schim van der Loeff, M.F.; Davidovich, U.; Hogewoning, A.; de Vries, H.J.C.; Schinkel, J.; Prins, M.; Van De Laar, T.J. MSM starting pre-exposure prophylaxis are at risk of hepatitis C virus infection. AIDS 2017, 31, 1603–1610. [CrossRef]
8. Vuyykeste, B.; Reyniers, T.; De Baetselier, I.; Nostlinger, C.; Crucitti, T.; Buyse, J.; Kenyon, C.; Wouters, K.; Laga, M. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: Results of a prospective cohort measuring adherence, sexual behaviour and STI incidence. J. Int. AIDS Soc. 2019, 22, e25407. [CrossRef]
9. Ramiere, C.; Charre, C.; Mailhees, P.; Bailly, F.; Radenne, S.; Uhres, A.C.; Brochier, C.; Godinot, M.; Chiarello, P.; Pradat, P.; et al. Patterns of Hepatitis C Virus Transmission in Human Immunodeficiency Virus (HIV)-infected and HIV-negative Men Who Have Sex With Men. Clin. Infect. Dis. 2019, 69, 2127–2135. [CrossRef]
10. van de Laar, T.; Pybus, O.; Bruisten, S.; Brown, D.; Nelson, M.; Bhagani, S.; Vogel, M.; Baumgarten, A.; Chais, M.-L.; Fisher, M.; et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009, 136, 1603–1617. [CrossRef]
11. Huleggie, S.J.; Claassen, M.A.; van den Berk, G.E.; van der Meer, J.T.; Posthouwer, D.; Lauw, F.N.; Leyten, E.M.; Koopmans, P.P.; Richter, C.; van Eeden, A.; et al. Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. J. Hepatol. 2016, 64, 807–812. [CrossRef]
12. Boerekamps, A.; De Wegheleire, A.; van den Berk, G.E.; Lauw, F.N.; Claassen, M.A.A.; Posthouwer, D.; Bierman, W.F.; Huleggie, S.J.; Popping, S.; Vrijer, D.A.C.M.V.D.; et al. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of boceprevir plus elbasvir (DAHHS2): An open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol. Hepatol. 2019, 4, 269–277. [CrossRef]
13. Christiansen, M.T.; Huleggie, S.J.; Schutten, M.; Einer-Jensen, K.; Tutill, H.J.; Breuer, J.; Rijnbers, B. Use of whole genome sequencing in the Dutch Acute HCV in HIV study: Focus on transmitted antiviral resistance. Clin. Microbiol. Infect. 2017, 23, 123.e1–123.e4. [CrossRef] [PubMed]
14. Popping, S.; Verwijs, R.; Cuypers, L.; Claassen, M.; van den Berk, G.; De Wegheleire, A.; Arends, J.E.; Boerekamps, A.; Molenkamp, R.; Koopmans, M.P.; et al. Transmission of NSSA resistance associated substitutions among men-who-have-sex-with-men recently infected with hepatitis C virus genotype 1a. Clin. Infect. Dis. 2020, 71, e215–e217. [CrossRef] [PubMed]
15. Altschul, S.F.; Gish, W.; Miller, W.; Myers, E.W.; Lipman, D.J. Basic local alignment search tool. *J. Mol. Biol.* **1990**, *215*, 403–410. [CrossRef]

16. Trifinopoulos, J.; Nguyen, L.T.; von Haeseler, A.; Minh, B.Q. W-IQ-TREE: A fast online phylogenetic tool for maximum likelihood analysis. *Nucleic Acids Res.* **2016**, *44*, W232–W235. [CrossRef] [PubMed]

17. Kalyaanamoorthy, S.; Minh, B.Q.; Wong, T.K.F.; von Haeseler, A.; Jermiin, L.S. ModelFinder: Fast model selection for accurate phylogenetic estimates. *Nat. Methods* **2017**, *14*, 587–589. [CrossRef]

18. Guindon, S.; Dufayard, J.F.; Lefort, V.; Anisimova, M.; Hordijk, W.; Gascuel, O. New algorithms and methods to estimate maximum-likelihood phylogenies: Assessing the performance of PhyML 3.0. *Syst. Biol.* **2010**, *59*, 307–321. [CrossRef]

19. Hassan, A.S.; Pybus, O.G.; Sanders, E.J.; Albert, J.; Esbjornsson, J. Defining HIV-1 transmission clusters based on sequence data. *AIDS 2017*, **31**, 1211–1222. [CrossRef]

20. CDC. MicrobeTrace: CDC; 2020. Available online: https://microbetrace.cdc.gov/MicrobeTrace/ (accessed on 27 January 2020).

21. van Sighem, A.; Wit, F.; Boyd, A.; Smit, C.; Matser, A.; Reiss, P. Monitoring Report 2019. *Human Immunodeficiency Virus (HIV)* Infection in The Netherlands. Amsterdam: Stichting HIV Monitoring. 2019. Available online: www.hiv-monitoring.nl (accessed on 26 August 2020).

22. Smit, C.; Boyd, A.; Rijnders, B.J.A.; van de Laar, T.J.W.; Leyten, E.M.; Bierman, W.F.; Brinkman, K.; Claassen, M.A.; Holland, J.D.; Boerекamps, A.; et al. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: A retrospective cohort study. *Lancet HIV* **2021**, *8*, e96–e105. [CrossRef]

23. Stephanie Popping, B.N.; Rijnders, B.; van Kampen, J.; Verbon, A.; Boucher, C.; van de Vijver, D. Targeted HCV core antigen monitoring among HIV-positive men who have sex with men is cost-saving. *J. Virus End.*** **2019**, *5*, 179–190. [CrossRef]

24. Salazar-Vizcaya, L.; Kouyos, R.D.; Fehr, J.; Braun, D.; Estill, J.; Bernasconi, E.; Delaloye, J.; Stöckle, M.; Schmid, P.; Rougemont, M.; et al. On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: A mathematical modelling study. *J. Viral Hepat.* **2018**, *25*, 10–18. [CrossRef]

25. Amsterdam Medisch Centrum, SOA AIDS Nederland. NoMoreC Project: 2018. Available online: https://nomorec.nl/home (accessed on 4 December 2018).

26. Jongen, V.W.; van Rooijen, M.S.; Schim van der Loeff, M.F.; Newsum, A.M.; de Vos Klootwijk, L.; Hoornenborg, E.; Hogewoning, A.; van der Valk, M.; Berk, G.E.V.D.; Prins, M.; et al. Evaluation of the Hepatitis C Testing Strategy for Human Immunodeficiency Virus-Positive Men Who Have Sex With Men at the Sexually Transmitted Infections Outpatient Clinic of Amsterdam, The Netherlands. *Sex. Transm. Dis.* **2020**, *47*, 587–595. [CrossRef] [PubMed]

27. Salazar-Vizcaya, L.; Kouyos, R.D.; Metzner, K.J.; Caraballo Cortes, K.; Boni, J.; Shah, C.; Fehr, J.; Braun, D.L.; Bernasconi, E.; Mbunkah, H.A.; et al. Changing trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era. *J. Infect. Dis.* **2019**, *220*, 91–99. [CrossRef]

28. Abravanel, F.; Mètivier, S.; Chauveau, M.; Péron, J.-M.; Izopet, J. Transmission of HCV NS5A Inhibitor–Resistant Variants Among HIV-Infected Men Who Have Sex With Men. *Clin. Infect. Dis.* **2016**, *63*, 1271–1272. [CrossRef]

29. Koopsen, J.; Parker, E.; Han, A.X.; van de Laar, T.; Russell, C.; Hoornenborg, E.; Prins, M.; van der Valk, M.; Schinkel, J. Hepatitis C Virus Transmission Among Men Who Have Sex With Men: Externally Exposures Introductions May Complicate Microelimination Efforts. *Clin. Infect. Dis.* **2021**, *72*, e1056–e1063. [CrossRef] [PubMed]

30. Cotte, L.; Cua, E.; Reynes, J.; Raffi, F.; Rey, D.; Delobel, P.; Gagneux-Brunon, A.; Jacomet, C.; Palich, R.; Laroche, H.; et al. Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. *Liver Int.* **2018**, **38**, 1736–1740. [CrossRef] [PubMed]

31. Charre, C.; Cotte, L.; Kramer, R.; Mialilhes, P.; Godinot, M.; Koffi, J.; Scholtès, C.; Ramiere, C. Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men. *PLoS ONE* **2018**, *13*, e0193040. [CrossRef]

32. Dutch Association of HIV Treating Physicians. HIV Pre-Expositem Prophylaxe (PrEP) Richtlijn Nederland. 2019. Available online: http://nvhiv.nl/wp-content/uploads/2019/04/PrEP-richtlijn-Nederland-versie-2-dd-15-april-2019.pdf (accessed on 26 August 2022).

33. de Vos, A.S.; van der Helm, J.J.; Matser, A.; Prins, M.; Kretzschmar, M.E. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? *Addiction* **2013**, *108*, 1070–1081. [CrossRef]

34. Grady, B.P.; Vanhommerig, J.W.; Schinkel, J.; Weegink, J.; Bruisten, S.M.; Lindenburg, C.E.; Prins, M. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. *Eur. J. Gastroenterol. Hepatol.* **2012**, *24*, 1302–1307. [CrossRef]

35. Vanhommerig, J.W.; Lambers, F.A.; Schinkel, J.; Geskus, R.B.; Arends, J.E.; van de Laar, T.J.; Lauw, F.N.; Brinkman, K.; Gras, L.; Rijnders, B.J.A.; et al. Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study. *Open Forum. Infect. Dis.* **2015**, *2*, ofv115. [CrossRef]